HER2/ErbB2 Chimeric Monoclonal Antibody
| Catalog number: | B2017751 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 g |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | CD340, Erb-B2 Receptor Tyrosine Kinase 2, Human Epidermal Growth Factor Receptor 2, Neu, Receptor Tyrosine-Protein Kinase ErbB-2 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kudo K, Imai C, Lorenzini P, Kamiya T, Kono K, Davidoff AM, Chng WJ, Campana D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing Cancer Res. 2014 Jan 1;74(1):93-103.
- Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Role of Fc receptors in HER2-targeted breast cancer therapy J Immunother Cancer. 2022 Jan;10(1):e003171.
- Rugo HS, Im SA, Cardoso F, Corts J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escriv-de-Roman S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petrkov K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial JAMA Oncol. 2021 Apr 1;7(4):573-584.
- Amiri MM, Bahadori T, Soltantoyeh T, Hosseini-Ghatar R, Golsaz-Shirazi F, Jeddi-Tehrani M, Shokri F. Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody Iran J Immunol. 2019 Mar;16(1):26-42.
- Amiri MM, Golsaz-Shirazi F, Soltantoyeh T, Hosseini-Ghatar R, Bahadori T, Khoshnoodi J, Navabi SS, Farid S, Karimi-Jafari MH, Jeddi-Tehrani M, Shokri F. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition Invest New Drugs. 2018 Apr;36(2):171-186.
- Kaneko MK, Suzuki H, Ohishi T, Nakamura T, Tanaka T, Kato Y. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models Int J Mol Sci. 2024 Feb 5;25(3):1941.
- Leung K. (64)Cu-1,4,7,10-Tetraazacyclododecane-N,N,N,N-tetraacetic acid-panitumumab 2010 Jun 25 [updated 2010 Sep 30]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 20042013.
- Kaneko MK, Suzuki H, Kato Y. Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H(2)Mab-250/H(2)CasMab-2 for Breast Cancers Monoclon Antib Immunodiagn Immunother. 2024 Apr;43(2):35-43.
- Leung K. Cy5.5-8-Amino-octanoic acid-Ser-Cys-Pro-Pro-Trp-Gln-Glu-Trp-His-Asn-Phe-Met-Pro-Phe-NH(2) 2012 Aug 21 [updated 2012 Nov 15]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 20042013.
